{"id":"memantine-once-daily","safety":{"commonSideEffects":[{"rate":"5–10%","effect":"Dizziness"},{"rate":"5–10%","effect":"Headache"},{"rate":"3–5%","effect":"Confusion"},{"rate":"3–5%","effect":"Constipation"},{"rate":"2–4%","effect":"Hypertension"},{"rate":"2–3%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL807","moleculeType":"Small molecule","molecularWeight":"179.31"},"_fixedAt":"2026-03-30T14:08:41.924640","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Memantine blocks the NMDA receptor ion channel in a use-dependent manner, allowing it to preferentially inhibit pathological overactivity of glutamate signaling while preserving normal synaptic transmission. This mechanism protects neurons from excitotoxic damage thought to contribute to cognitive decline in neurodegenerative diseases. The drug is thought to restore a more normal balance of glutamatergic neurotransmission in the brain.","oneSentence":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:16.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Alzheimer's disease"}]},"_fixedFields":["pubmed(47)"],"trialDetails":[{"nctId":"NCT04302870","phase":"PHASE2, PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","enrollment":1150},{"nctId":"NCT05063851","phase":"PHASE2","title":"The Use of Memantine for Prevention of Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2021-10-11","conditions":"Alzheimer Disease","enrollment":32},{"nctId":"NCT07251023","phase":"PHASE3","title":"Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia","status":"RECRUITING","sponsor":"Bigespas LTD","startDate":"2025-11-20","conditions":"Alzheimer Type Dementia","enrollment":450},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT06007846","phase":"PHASE2, PHASE3","title":"A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2023-07-31","conditions":"Hepatocellular Carcinoma, Cirrhosis","enrollment":12},{"nctId":"NCT06862960","phase":"PHASE2","title":"Ozanimod in Patients With Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"ChenXiaoChun","startDate":"2025-07-01","conditions":"Alzheimer Disease","enrollment":40},{"nctId":"NCT02360215","phase":"PHASE3","title":"Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2015-07","conditions":"Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm","enrollment":518},{"nctId":"NCT06275035","phase":"PHASE3","title":"Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-02-22","conditions":"Neurocognitive Dysfunction","enrollment":101},{"nctId":"NCT06679387","phase":"PHASE2","title":"\"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients\"","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-30","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":80},{"nctId":"NCT06594172","phase":"PHASE2","title":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2024-09-10","conditions":"Radiation Disease, Cognitive Impairment, Drug Effect","enrollment":67},{"nctId":"NCT04792645","phase":"PHASE2","title":"Memantine in Body Focused Repetitive Behaviors","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2021-06-15","conditions":"Trichotillomania (Hair-Pulling Disorder), Dermatillomania","enrollment":100},{"nctId":"NCT06337994","phase":"PHASE3","title":"Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Treatment of Cognitive Deficits After Traumatic Brain Injury","enrollment":60},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT04033419","phase":"PHASE2","title":"Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-25","conditions":"Cognitive Decline, Chemo-brain","enrollment":55},{"nctId":"NCT02118727","phase":"PHASE2","title":"Therapy in Amyotrophic Lateral Sclerosis (TAME)","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-11-07","conditions":"Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia","enrollment":89},{"nctId":"NCT03986424","phase":"PHASE3","title":"Local Study of Akatinol Memantine in VaD in Russia","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2018-01-23","conditions":"Vascular Dementia","enrollment":130},{"nctId":"NCT05430867","phase":"PHASE4","title":"Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-07-01","conditions":"Treatment, Efficacy, Safety","enrollment":150},{"nctId":"NCT03221894","phase":"","title":"A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2017-07-15","conditions":"Alzheimer Disease","enrollment":120},{"nctId":"NCT02080364","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease","status":"TERMINATED","sponsor":"vTv Therapeutics","startDate":"2015-04","conditions":"Alzheimer's Disease","enrollment":880},{"nctId":"NCT04737967","phase":"PHASE2, PHASE3","title":"The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Mendel AI","startDate":"2021-02-15","conditions":"Oncology Pain, Chemotherapy-induced Peripheral Neuropathy","enrollment":60},{"nctId":"NCT04687566","phase":"PHASE2, PHASE3","title":"Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-08-11","conditions":"Amphetamine Addiction, Pharmacotherapy","enrollment":120},{"nctId":"NCT03858270","phase":"PHASE3","title":"Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2019-04-01","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT04417543","phase":"PHASE1","title":"Effect of Memantine on Cognitive Impairment in Patients With Epilepsy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-10-01","conditions":"Epilepsy","enrollment":100},{"nctId":"NCT02258828","phase":"PHASE4","title":"An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder","status":"COMPLETED","sponsor":"Sriram Ramaswamy","startDate":"2005-07","conditions":"PTSD","enrollment":26},{"nctId":"NCT00630955","phase":"PHASE2","title":"Family History Study of Alcohol Consumption Using Memantine","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-06","conditions":"Alcohol Drinking","enrollment":111},{"nctId":"NCT03247218","phase":"PHASE2","title":"A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2018-02-02","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT03802162","phase":"PHASE1","title":"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-02-15","conditions":"Alzheimer's Disease (AD)","enrollment":60},{"nctId":"NCT01902004","phase":"PHASE4","title":"Brain Aging and Treatment Response in Geriatric Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-10","conditions":"Mild Cognitive Impairment (MCI), Depression","enrollment":115},{"nctId":"NCT01592747","phase":"PHASE2","title":"Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-09","conditions":"Autistic Disorder, Autism, Asperger's Disorder","enrollment":479},{"nctId":"NCT02553928","phase":"PHASE4","title":"Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-10","conditions":"Alzheimer Dementia (AD)","enrollment":62},{"nctId":"NCT03686774","phase":"PHASE2","title":"Memantine and Post-mastectomy Neuropathic Pain","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-02-15","conditions":"Neuropathic Pain","enrollment":150},{"nctId":"NCT03316898","phase":"PHASE1","title":"A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2018-09-30","conditions":"Alzheimer's Disease","enrollment":""},{"nctId":"NCT02162251","phase":"","title":"Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2013-06-01","conditions":"Alzheimer's Desease","enrollment":3482},{"nctId":"NCT02079246","phase":"PHASE3","title":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-04-07","conditions":"Alzheimer's Disease","enrollment":1463},{"nctId":"NCT00586066","phase":"PHASE4","title":"Memantine and Cognitive Dysfunction in Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-11","conditions":"Bipolar Disorder","enrollment":72},{"nctId":"NCT00566852","phase":"PHASE3","title":"Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-03","conditions":"Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity","enrollment":554},{"nctId":"NCT02615847","phase":"PHASE2","title":"Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2015-08","conditions":"Sickle Cell Disease","enrollment":9},{"nctId":"NCT01054599","phase":"NA","title":"Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?","status":"COMPLETED","sponsor":"American Academy of Neurology","startDate":"2009-01","conditions":"Epilepsy","enrollment":29},{"nctId":"NCT00242632","phase":"NA","title":"Treatment With Namenda in Women at Risk for Cognitive Decline","status":"COMPLETED","sponsor":"Stanford University","startDate":"2004-06","conditions":"Dementia","enrollment":22},{"nctId":"NCT01677754","phase":"PHASE2","title":"A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-24","conditions":"Alzheimer's Disease","enrollment":542},{"nctId":"NCT02246075","phase":"PHASE2","title":"Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine","status":"WITHDRAWN","sponsor":"FORUM Pharmaceuticals Inc","startDate":"2015-07","conditions":"Alzheimer's Disease, Dementia, Cognition","enrollment":""},{"nctId":"NCT01592773","phase":"PHASE2","title":"Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Autism Spectrum Disorder (ASD), Autism, Autistic Disorder","enrollment":747},{"nctId":"NCT01592786","phase":"PHASE2","title":"An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-06","conditions":"Autism Spectrum Disorder (ASD), Autism, Autistic Disorder","enrollment":906},{"nctId":"NCT01999894","phase":"PHASE2","title":"Open-label Study of Safety and Tolerability of Memantine in Children With Autism","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-11","conditions":"Autism, Pediatric Autism","enrollment":102},{"nctId":"NCT00872898","phase":"PHASE2","title":"Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-04","conditions":"Autism","enrollment":124},{"nctId":"NCT00857649","phase":"PHASE3","title":"Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2003-12","conditions":"Alzheimer's Disease","enrollment":369},{"nctId":"NCT01261741","phase":"PHASE2","title":"Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2010-11","conditions":"Memory Disorder, Retention Disorder, Cognitive, Subjective Cognitive Impairment","enrollment":299},{"nctId":"NCT00855686","phase":"PHASE4","title":"Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-01","conditions":"Parkinson's Disease Dementia, Dementia With Lewy Bodies","enrollment":199},{"nctId":"NCT00857233","phase":"PHASE3","title":"Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2004-06","conditions":"Alzheimer's Disease","enrollment":297},{"nctId":"NCT00624026","phase":"PHASE3","title":"Memantine - Communication Study","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2007-11","conditions":"Alzheimer's Disease","enrollment":107},{"nctId":"NCT00322153","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2005-06","conditions":"Dementia of the Alzheimer's Type","enrollment":677}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"recentPublications":[{"date":"2026 Feb 11","pmid":"41673604","title":"Memantine to preserve memory and neurocognition following craniospinal irradiation (MEMENTO): a phase 3 randomized controlled trial.","journal":"BMC cancer"},{"date":"2024 Jun","pmid":"38883494","title":"Role of Memantine in Limiting Cochleotoxicity in Rats.","journal":"Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India"},{"date":"2024","pmid":"38465812","title":"[Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia].","journal":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova"},{"date":"2023 Oct-Dec","pmid":"38059250","title":"Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.","journal":"Journal of neurosciences in rural practice"},{"date":"2023 Aug","pmid":"37229803","title":"Unfavorable effects of memantine on the skeletal system in female rats.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lu 00-800","Ebixa ®","Ebix ®"],"phase":"marketed","status":"active","brandName":"Memantine (once daily)","genericName":"Memantine (once daily)","companyName":"H. Lundbeck A/S","companyId":"h-lundbeck-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity. Used for Moderate to severe Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}